Boston Scientific Plunges After Cautious 2026 Guidance Disappoints Investors

Medical device maker's stock falls 17.5% despite Q4 earnings beat

Feb. 4, 2026 at 5:23pm

Got story updates? Submit your updates here. ›

Boston Scientific, a leading medical device company, saw its stock plunge 17.5% on Wednesday after providing cautious 2026 guidance that fell short of analyst expectations, despite reporting strong Q4 earnings that beat Wall Street estimates. The company's cautious outlook and weaker-than-expected electrophysiology sales reset growth assumptions, leading to a sharp sell-off in the stock.

Why it matters

Boston Scientific is a bellwether in the medical device industry, and its performance is closely watched by investors. The company's cautious guidance, even after a strong Q4, highlights the challenges facing the sector and the sensitivity of investors to any signs of slowing growth.

The details

Boston Scientific reported Q4 earnings that beat expectations, with sales and adjusted EPS growing 16% and 14% respectively. However, the company's Q1 and 2026 EPS guidance came in one penny shy of analysts' estimates, leading to a sharp 17.5% drop in the stock price. The company's core Cardiovascular segment grew sales by 18%, and its MedSurg unit saw a 12% increase in revenue. Management also guided for $4.2 billion in free cash flow in 2026.

  • Boston Scientific reported Q4 2025 earnings on February 4, 2026.

The players

Boston Scientific

A leading medical device company that specializes in interventional specialties.

Got photos? Submit your photos here. ›

What they’re saying

“Despite growing sales and adjusted EPS by 16% and 14% in Q4 -- easily beating Wall Street's estimates -- Boston Scientific stock dropped 18% on Wednesday due to 'weak' guidance.”

— Josh Kohn-Lindquist, Author (fool.com)

The takeaway

Boston Scientific's cautious 2026 guidance, despite strong Q4 results, highlights the sensitivity of investors to any signs of slowing growth in the medical device industry. The company's performance is closely watched as a bellwether for the sector, and its stock price reaction underscores the need for companies to manage investor expectations carefully.